| Bioactivity | Cemdisiran, terminal sugar modification- is an investigational N-acetylgalactosamine-conjugated RNAi drug. Cemdisiran, a siRNA-targeting C5 mRNA, suppresses liver production of complement component C5[1]. |
| Name | Cemdisiran, terminal sugar modification- |
| CAS | 1436858-07-9 |
| Formula | C78H140N11O34P |
| Molar Mass | 1806.97 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kishor Devalaraja-Narashimha ,et al. Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates. PLoS One. 2022 Jun 16;17(6):e0269749. [2]. Ellen S Smith, et al. Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine. Cancers (Basel). 2022 Mar 21;14(6):1588. |
Cemdisiran, terminal sugar modification-
CAS: 1436858-07-9 F: C78H140N11O34P W: 1806.97
Cemdisiran, terminal sugar modification- is an investigational N-acetylgalactosamine-conjugated RNAi drug. Cemdisiran, a
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.